14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GENZ vs DNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DNA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–2 Matrix Metrics)
DNA Overall Winner
6-Pillar Tally: GENZ 2 – 3 DNA (1 Tie)
Matrix Metrics: GENZ 2 – 6 DNA
As of Nov 16, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) is the stronger overall head-to-head candidate over GENZ (GENZ) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GENZ carries a Unified Composite Score of 44.3/100 (HOLD) at $36.39 (N/M Forward P/E, N/A operating margin), whereas DNA carries 57.4/100 (HOLD) at $8.50 (N/M Forward P/E, -202.5% operating margin).
Technical & Structure Timing Caution: GENZ is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 42.5); meanwhile DNA is in a Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GENZ vs DNA. Trailing 12-month operating profitability (GENZ N/A vs DNA -202.5%) and valuation multiples (GENZ N/M vs DNA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
DNA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $623.0M market capitalization and -202.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ GENZ vs DNA Key Questions & Quantitative Answers
As of Nov 16, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) is the stronger overall head-to-head candidate over GENZ (GENZ) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GENZ carries a Unified Composite Score of 44.3/100 (HOLD) at $36.39 (N/M Forward P/E, N/A operating margin), whereas DNA carries 57.4/100 (HOLD) at $8.50 (N/M Forward P/E, -202.5% operating margin). Technical & Structure Timing Caution: GENZ is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 42.5); meanwhile DNA is in a Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DNA leads the Growth & Scale pillar: GENZ posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with DNA at -5.7% YoY revenue growth and +0.0% YoY earnings growth on $131M TTM revenue (69.8% gross margin, -202.5% operating margin). On trailing 12-month operating scale, GENZ generates N/A in USD-normalized revenue versus $131M for DNA. In operating R&D and SG&A reinvestment, GENZ deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNA.
DNA screens cheaper on headline valuation multiples. GENZ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas DNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GENZ (N/A ROE) versus DNA (-58.2% ROE) capital efficiency.
In options market volatility and institutional positioning, GENZ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.85β · 27% Vol realized risk). By comparison, DNA carries 119.2% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.14β · 152% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.